HSPA8 Monoclonal Antibody is a laboratory-generated immunoglobulin that selectively binds to the HSPA8 protein (Heat Shock Protein Family A Member 8), also known as HSC70. This constitutively expressed chaperone regulates protein folding, degradation via chaperone-mediated autophagy (CMA), and stress adaptation . The antibody is produced using hybridoma technology, ensuring high specificity for human, mouse, and rat HSPA8 isoforms .
The development process involves:
Immunization: Mice are immunized with recombinant human HSPA8 protein (amino acids 2–646) or synthesized peptides .
Hybridoma Generation: Splenocytes from immunized mice are fused with myeloma cells to create antibody-producing hybridomas .
Purification: Antibodies are isolated using Protein A/G affinity chromatography, achieving >95% purity .
Subcellular Tracking: HSPA8 monoclonal antibodies have identified nuclear translocation of HSPA8 during heat shock or oxidative stress, essential for cell survival .
Autophagy Regulation: Studies using these antibodies demonstrated HSPA8’s role in forming liquid-liquid phase separation (LLPS) complexes with RHOB and BECN1, enhancing anti-bacterial autophagy .
Autoimmune Diseases: Antibody-based assays revealed elevated HSPA8 levels in lupus-prone mice, linked to dysregulated CMA and pathogenic autoantibody production .
Viral Entry: HSPA8 monoclonal antibodies blocked infectious bronchitis virus (IBV) infection by disrupting viral attachment to host cell membranes .
Sensitivity: Detects endogenous HSPA8 at concentrations as low as 0.1 ng/µL in Western blotting (WB) .
Cross-Reactivity: Validated for human, mouse, rat, bovine, and pig samples .
Functional Assays: Used in co-immunoprecipitation (Co-IP) to map HSPA8 interactions with NLRC4 (inflammasome component) and BECN1 (autophagy protein) .
Species Restrictions: While cross-reactive with multiple species, performance in non-mammalian systems remains untested .
Batch Variability: Commercial products from different vendors show variability in recommended dilutions (e.g., 1:500–1:256K for WB) .
Therapeutic Targeting: Explore HSPA8 inhibition/activation strategies using antibody-guided drug delivery .
Diagnostic Biomarkers: Investigate HSPA8 overexpression in autoimmune diseases or cancer using IHC-validated antibodies .
Viral Antagonism: Develop antibody-based inhibitors against HSPA8-dependent viral entry mechanisms .
This HSPA8 monoclonal antibody was developed using hybridoma technology. The antibody-producing hybridomas were generated by fusing myeloma cells with spleen cells from immunized mice. The mice were immunized with recombinant human HSPA8 protein (amino acids 2-646). This HSPA8 monoclonal antibody is designed to detect endogenous levels of human HSPA8 protein. It has been purified using protein G and rigorously validated for its performance in ELISA, Western blotting, immunohistochemistry, immunofluorescence, and flow cytometry applications. Its purity exceeds 95%.
The HSPA8 protein primarily functions as a chaperone within the cell, assisting in protein folding, transport, and degradation. It accomplishes this by binding to nascent polypeptide chains or misfolded proteins, guiding them through various cellular processes. HSPA8 plays a critical role in maintaining cellular homeostasis by preventing the accumulation of misfolded or aggregated proteins, which can lead to cellular dysfunction and disease. It is also involved in the regulation of apoptosis, antigen processing, and cell signaling.